Sort   by:  
 Page size 
UnknownMolecular characteristics of Neisseria meningitidis in Qatar.
The aim of the current study is to review the molecular characteristics of Neisseria meningitidis (N. meningitidis) in Hamad Medical Corporation, which is the provider of secondary and tertiary care in the state of Qatar. A total of 39 isolates of N. meningitidis from the period of 2013 to 2018 were...
S-EPMC7910605 | biostudies-literature
UnknownSARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy.

Background

Reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been documented, raising public health concerns. SARS-CoV-2 reinfections were assessed in a cohort of antibody-positive persons in Qatar.

Methods

All SARS-CoV-2 antibody-positive persons f...
S-EPMC8079668 | biostudies-literature
UnknownEffects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta SARS-CoV-2 infections: an observational study.

Background

Protection against SARS-CoV-2 symptomatic infection and severe COVID-19 of previous infection, mRNA two-dose vaccination, mRNA three-dose vaccination, and hybrid immunity of previous infection and vaccination were investigated in Qatar for the Alpha, Beta, and Delta variants.

M...

S-EPMC10404859 | biostudies-literature
UnknownPopulation immunity of natural infection, primary-series vaccination, and booster vaccination in Qatar during the COVID-19 pandemic: an observational study.

Background

Waning of natural infection protection and vaccine protection highlight the need to evaluate changes in population immunity over time. Population immunity of previous SARS-CoV-2 infection or of COVID-19 vaccination are defined, respectively, as the overall protection against reinf...
S-EPMC10393554 | biostudies-literature
UnknownProtection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study.

Background

Understanding protection conferred by natural SARS-CoV-2 infection versus COVID-19 vaccination is important for informing vaccine mandate decisions. We compared protection conferred by natural infection versus that from the BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) vaccin...
S-EPMC9651957 | biostudies-literature
UnknownSARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals.
The study objective was to the assess level of detectable severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in the urban population of Qatar. Antibody testing was performed on residual blood specimens for 112,941 individuals (∼10% of Qatar's urban population) attending for rout...
S-EPMC8142077 | biostudies-literature
UnknownEffectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants.
Not available
S-EPMC8117967 | biostudies-literature
UnknownCOVID-19 risk score as a public health tool to guide targeted testing: A demonstration study in Qatar.
We developed a Coronavirus Disease 2019 (COVID-19) risk score to guide targeted RT-PCR testing in Qatar. The Qatar national COVID-19 testing database, encompassing a total of 2,688,232 RT-PCR tests conducted between February 5, 2020-January 27, 2021, was analyzed. Logistic regression analyses were i...
S-EPMC9295939 | biostudies-literature
UnknownAssessing the performance of a serological point-of-care test in measuring detectable antibodies against SARS-CoV-2.
This study investigated the performance of a rapid point-of-care antibody test, the BioMedomics COVID-19 IgM/IgG Rapid Test, in comparison with a high-quality, validated, laboratory-based platform, the Roche Elecsys Anti-SARS-CoV-2 assay. Serological testing was conducted on 709 individuals. Concord...
S-EPMC8803198 | biostudies-literature
UnknownImmune Imprinting and Protection against Repeat Reinfection with SARS-CoV-2.
Not available
S-EPMC9634858 | biostudies-literature
Sort   by:  
 Page size